ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Characteristics of six separate randomized trials of three versus six months of adjuvant chemotherapy for resected colon cancer

Characteristics of six separate randomized trials of three versus six months of adjuvant chemotherapy for resected colon cancer
Trial, reference Number Chemotherapy regimens CAPOX (%) Disease stage Tumor location Enrolling country Clinical trial information
TOSCA[1] 3759 CAPOX or FOLFOX4 35 III, high-risk II Colon Italy NCT00646607
SCOT[2] 6088 CAPOX or mFOLFOX6 67 III, high-risk II Colon United Kingdom, Denmark, Spain, Sweden, Australia, New Zealand NCT00749450
IDEA[3] 2022 CAPOX or mFOLFOX6 10 III Colon or rectum France NCT00958737
C80702 2500 mFOLFOX6 0 III, high-risk II Colon United States, Canada NCT01150045
HORG[4] 1115 CAPOX or FOLFOX4 65 III, high-risk II Colon Greece NCT01308086
ACHIEVE[5] 1313 CAPOX or mFOLFOX6 75 III Colon Japan UMIN 000008543
CAPOX: capecitabine plus oxaliplatin; FOLFOX: oxaliplatin plus leucovorin and short-term infusional fluorouracil; mFOLFOX: modified FOLFOX; IDEA: International Duration Evaluation of Adjuvant Chemotherapy; C80702: Cancer and Leukemia Group B/Southwest Oncology Group trial C80702; HORG: Hellenic Oncology Research Group.
References:
  1. Sobrero AF, Lonardi S, Rosati G, et al. FOLFOX or CAPOX in Stage II to III Colon Cancer: Efficacy Results of the Italian Three or Six Colon Adjuvant Trial. J Clin Oncol 2018; 36:1478.
  2. Iveson TJ, Kerr RS, Saunders MP, et al. 3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomized, phase 3, non-inferiority trial. Lancet Oncol 2018; 19:562. 
  3. André T, Vernerey D, Mineur L, et al. Three Versus 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Patients With Stage III Colon Cancer: Disease-Free Survival Results From a Randomized, Open-Label, International Duration Evaluation of Adjuvant (IDEA) France, Phase III Trial. J Clin Oncol 2018; 36:1469.
  4. Souglakos J, Boukovinas I, Kakolyris S, et al. Three versus six months adjuvant FOLFOX or CAPOX for high risk stage II and stage III colon cancer patients: the efficacy results of Hellenic Oncology Research Group (HORG) participation to the International Duration Evaluation of Adjuvant chemotherapy (IDEA) project. Ann Oncol 2019; 30:1304.
  5. Yoshino T, Yamanaka T, Oki E, et al. Efficacy and long-term peripheral sensory neuropathy of 3 vs 6 months of oxaliplatin-based adjuvant chemotherapy for colon cancer: the ACHIEVE phase 3 randomized clinical trial. JAMA Oncol 2019; 5:1574.
Graphic 113633 Version 8.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟